دورية أكاديمية
أعرض في EDS

TB/FLU-06E Influenza Vector-Based Vaccine in the Complex Therapy of Drug-Susceptible and Drug-Resistant Experimental Tuberculosis.

التفاصيل البيبلوغرافية
العنوان: TB/FLU-06E Influenza Vector-Based Vaccine in the Complex Therapy of Drug-Susceptible and Drug-Resistant Experimental Tuberculosis.
المؤلفون: Shurygina AS; Smorodintsev Research Institute of Influenza, The Ministry of Health of the Russian Federation, 197022 Saint-Petersburg, Russia., Zabolotnykh NV; Saint-Petersburg State Research Institute of Phthisiopulmonology, The Ministry of Health of the Russian Federation, 194064 Saint-Petersburg, Russia., Vinogradova TI; Saint-Petersburg State Research Institute of Phthisiopulmonology, The Ministry of Health of the Russian Federation, 194064 Saint-Petersburg, Russia., Vitovskaya ML; Saint-Petersburg State Research Institute of Phthisiopulmonology, The Ministry of Health of the Russian Federation, 194064 Saint-Petersburg, Russia., Dogonadze MZ; Saint-Petersburg State Research Institute of Phthisiopulmonology, The Ministry of Health of the Russian Federation, 194064 Saint-Petersburg, Russia., Vasilyev KA; Smorodintsev Research Institute of Influenza, The Ministry of Health of the Russian Federation, 197022 Saint-Petersburg, Russia., Buzitskaya ZV; Smorodintsev Research Institute of Influenza, The Ministry of Health of the Russian Federation, 197022 Saint-Petersburg, Russia., Yablonskiy PK; Saint-Petersburg State Research Institute of Phthisiopulmonology, The Ministry of Health of the Russian Federation, 194064 Saint-Petersburg, Russia., Lioznov DA; Smorodintsev Research Institute of Influenza, The Ministry of Health of the Russian Federation, 197022 Saint-Petersburg, Russia., Stukova MA; Smorodintsev Research Institute of Influenza, The Ministry of Health of the Russian Federation, 197022 Saint-Petersburg, Russia.
المصدر: Pharmaceutics [Pharmaceutics] 2024 Jun 25; Vol. 16 (7). Date of Electronic Publication: 2024 Jun 25.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101534003 Publication Model: Electronic Cited Medium: Print ISSN: 1999-4923 (Print) Linking ISSN: 19994923 NLM ISO Abbreviation: Pharmaceutics Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: The steady rise of drug-resistant tuberculosis (TB), which renders standard therapy regimens ineffective, necessitates the development of innovative treatment approaches. Immunotherapeutic vaccines have the potential to effectively regulate the anti-TB immune response and enhance the efficacy of anti-TB treatment. In the present study, we aimed to evaluate the potency of the mucosal vector vaccine TB/FLU-06E as part of a complex treatment regimen for drug-susceptible (DS) or drug-resistant (DR) tuberculosis in C57BL/6 mice. Incorporating TB/FLU-06E into the treatment protocol significantly increased the effectiveness of therapy for both forms of tuberculosis. It was evidenced by higher survival rates and reduced pulmonary bacterial load (1.83 lg CFU for DS tuberculosis and 0.93 lg CFU for DR tuberculosis). Furthermore, the treatment reduced pathomorphological lesions in the lungs and stimulated the local and systemic T-helper 1 (Th1) and cytotoxic T-lymphocyte (CTL) anti-TB immune responses. Thus, therapeutic immunization with the TB/FLU-06E vaccine significantly enhances the efficacy of tuberculosis treatment, which is particularly important in DR tuberculosis.
References: Front Immunol. 2016 Oct 03;7:401. (PMID: 27752256)
Eur J Immunol. 2015 Apr;45(4):1069-81. (PMID: 25631937)
Int J Tuberc Lung Dis. 2018 Feb 1;22(2):139-150. (PMID: 29506610)
Front Immunol. 2020 Oct 22;11:566319. (PMID: 33193338)
J Biol Chem. 2014 Oct 31;289(44):30190-30195. (PMID: 25202011)
Nat Commun. 2016 Dec 22;7:13894. (PMID: 28004802)
Int J Mycobacteriol. 2022 Jan-Mar;11(1):108-112. (PMID: 35295032)
Immunol Lett. 2014 Mar-Apr;158(1-2):88-94. (PMID: 24345702)
Nat Commun. 2019 Apr 23;10(1):1823. (PMID: 31015452)
Front Immunol. 2020 Aug 27;11:1925. (PMID: 32973795)
Eur Respir Rev. 2018 Jun 13;27(148):. (PMID: 29898905)
Int J Mol Sci. 2023 Apr 18;24(8):. (PMID: 37108602)
Probl Tuberk Bolezn Legk. 2008;(12):30-4. (PMID: 19230185)
Adv Exp Med Biol. 2013;783:141-63. (PMID: 23468108)
Semin Immunopathol. 2015 May;37(3):239-49. (PMID: 25917388)
Immunol Lett. 2017 Dec;192:52-60. (PMID: 29106984)
Epidemiol Infect. 2020 Feb 19;148:e50. (PMID: 32070443)
Sci Rep. 2016 Sep 07;6:32725. (PMID: 27601302)
J Biol Chem. 2006 Apr 21;281(16):10669-81. (PMID: 16431923)
PLoS Pathog. 2017 Nov 27;13(11):e1006704. (PMID: 29176787)
Immune Netw. 2018 Apr 03;18(2):e17. (PMID: 29732235)
Nat Commun. 2015 Oct 13;6:8533. (PMID: 26460802)
Lancet Infect Dis. 2022 Jul;22(7):e191-e196. (PMID: 35248168)
J Infect. 2013 Jun;66(6):475-86. (PMID: 23462597)
JCI Insight. 2020 Jul 23;5(14):. (PMID: 32554933)
Front Immunol. 2019 Oct 02;10:2350. (PMID: 31632413)
J Exp Med. 2023 Dec 4;220(12):. (PMID: 37843832)
Front Immunol. 2014 Apr 22;5:180. (PMID: 24795723)
Trans R Soc Trop Med Hyg. 2016 Mar;110(3):186-91. (PMID: 26884499)
Front Microbiol. 2017 Nov 17;8:2266. (PMID: 29204139)
Nat Immunol. 2011 Jun 12;12(7):639-46. (PMID: 21666689)
Clin Vaccine Immunol. 2006 Aug;13(8):898-904. (PMID: 16893990)
Front Immunol. 2022 Jun 24;13:878471. (PMID: 35812462)
Front Immunol. 2018 Mar 09;9:459. (PMID: 29593722)
Vaccines (Basel). 2018 May 24;6(2):. (PMID: 29795025)
Pol J Microbiol. 2022 May 31;71(2):205-215. (PMID: 35675816)
J Biol Chem. 2019 May 24;294(21):8555-8563. (PMID: 30975902)
Acc Chem Res. 2021 May 18;54(10):2361-2376. (PMID: 33886255)
J Immunol. 2019 May 1;202(9):2519-2526. (PMID: 31010841)
Front Immunol. 2020 Nov 06;11:585359. (PMID: 33240275)
Front Immunol. 2024 Apr 03;15:1383098. (PMID: 38633252)
Front Immunol. 2018 Jan 15;8:1973. (PMID: 29379507)
Nat Med. 2004 Sep;10(9):927-34. (PMID: 15311275)
Immunology. 2018 Mar;153(3):325-336. (PMID: 28881482)
Front Immunol. 2020 Jun 30;11:1325. (PMID: 32695111)
Tuberculosis (Edinb). 2006 May-Jul;86(3-4):236-46. (PMID: 16677861)
PLoS Pathog. 2016 Jan 08;12(1):e1005380. (PMID: 26745507)
PLoS One. 2013 Dec 12;8(12):e80579. (PMID: 24349004)
Eur J Immunol. 2010 Aug;40(8):2211-20. (PMID: 20540114)
Biomolecules. 2023 Jun 09;13(6):. (PMID: 37371548)
معلومات مُعتمدة: 121112600145-2 Ministry of Health of the Russian Federation
فهرسة مساهمة: Keywords: ESAT6; TB-specific immunotherapy; drug-resistant tuberculosis; influenza vector; mucosal vaccine
تواريخ الأحداث: Date Created: 20240727 Latest Revision: 20240729
رمز التحديث: 20240729
مُعرف محوري في PubMed: PMC11279844
DOI: 10.3390/pharmaceutics16070857
PMID: 39065554
قاعدة البيانات: MEDLINE
الوصف
تدمد:1999-4923
DOI:10.3390/pharmaceutics16070857